Description: Recombinant monoclonal antibody to RSV. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma RSHZ19 (Felvizumab). This is a Fab fragment with a his-tag.
Species and Isotype: Human Fab fragment, His-Tagged, kappa
Clone Number: RSHZ19 (Felvizumab)
UniProt Accession Number of Target Protein:
Published Application(s): functional; ELISA
Published Species Reactivity: RSV
Immunogen: This antibody was prepared by the humanization of an F protein-specific murine MAb, RSV19. More specifically, molecular techniques were used to insert the complementarity determining regions from murine RSV19 into a human IgG1 heavy and k light chain-variable domain framework.
Specificity: This antibody is specific for the conserved fusion (F) protein of RSV.
Application Notes: Though shown to be safe and well-tolerated (Everitt, 1996) and protective against RSV infection in BALB/c mice and cotton rats (Wyde, 1995), this antibody did not demonstrate efficacy in a Phase 3 study (Reichert, 2008). In in vitro studies, palivizumab, another humanized Mab specific for the F protein of RSV, was 4 to 5-fold more potent than felvizumab in neutralising RSV (Scott, 1999).
Antibody First Published in:
Tempest et al. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnology (N Y). 1991 Mar;9(3):266-71 PMID:1367535 Note on publication: Describes the original production of the humanized anti-RSV antibody from murine RSV19.

Product Form

Purification: Purified by Immobilized Metal Affinity Chromatography
Supplied in: PBS with preservative (0.02% Proclin 300)
Storage Recommendation: Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C
Concentration: See vial label.